| Other Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Why Do We Measure Performance, Anyway? |
|
Other Articles - Why Do We Measure Performance, Anyway?
Why do we measure organisational performance? The first answers that pop into your head might be: * you can't manage what you don't measure * what you measure gets done * we have to be accountable * they have to According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product be held accountable * they told us to These aren't the answers to the question this article asks. The reasons why so many organisations - particularly high performing organisations - measure things are more authent ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ic, more fundamental and more motivating than those listed above. To avoid knowing too late At a government agency executive meeting I attended, participants were evaluating whether an end of year revenue target ha lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. been met. No it hadn't, and they did have lots of reasons here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe versation more frequently throughout the year, perhaps they would have had time to create some strategies to better understand what was happening in their market and find new avenues of revenue generation. Annual ev d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro luation, or end-of-project evaluation is always too late to give you choices about changing your course. Are targets just about playing numbers games, or do they really represent important changes to ensure future he ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc alth? The above organisation is no longer in existence. Perhaps if they'd treated their revenue target more seriously, they might still be around. Frequently reported measures can give us early warning signs about w easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ether what we are doing is actually making the differences it's supposed to, early enough that we have the chance to modify or stop doing it if the intended results are not forthcoming. To avoid knowing too little nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically My friend works in a wholesale technology business that operates out of two cities over 1000km apart, with a staff of about 25 people and they sell approximately 50 product lines. The directors of this company only m and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ asure typical balance sheet stuff. Their staff complain incessantly about product returns, warranty service workload and availability of spare parts. Do they measure any of these non-financial things? No. They reckon ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi they don't need to, because it's a small business and they can see what's going on by walking around. But the same simple problems that plagued them six years ago are still plaguing them. Can you be everywhere at t ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a he same time, all the time in your organisation? Of course not. Most of what goes on in our organisations our physical senses (sight, hearing, touch, etc...) can't absorb or even detect with sufficient reliability fo dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod us to understand them. A small suite of performance measures help us know far more about what is going on with the health of our organisation's processes, than our own eyes and ears ever could, with any reasonable cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin amount of reliability. To know the right things A manager in the rail freight industry faced a typical problem for that industry several years ago: they were running out of capacity to move all their customers' pro tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen uce. The typical solution to this problem is to invest in more rollingstock. Millions and millions of dollars worth. But he didn't take the typical solution. Instead, he measured and studied the way the system worked t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel until he discovered that it wasn't how many wagons you had, but how quickly you could cycle those wagons through, that impacted the capacity. So he didn't need to buy new wagons because he did find a way to cycle th ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust wagons through the system much faster, ending up with even more capacity than they actually needed. How well do the decision makers in your organisation learn about what works and what doesn't work in fixing perfor y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products mance problems? Trial and error? Following traditional, already-proven strategies? How much real learning do they do about the real leverage points of unacceptable performance? Well chosen performance measures, that . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de monitor the root causes of the most important organisational health results, are measures that focus us on the things we really need to know. They help us break away from knowing things that really don't make much of elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip a difference. Why do you measure performance? If you aren't measuring to know enough about the right things, and frequently enough to do something about them, then perhaps you're not actually measuring performance tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Create a Culture for Success: How to Win Big Using 4 Small Steps You Had a Great Job Interview - Now What? Hiring the Best - Interviewing Strategies that WORK!
|